Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged as promising therapeutic candidates for the treatment of obesity and diabetes. We developed a novel stable and soluble glucagon receptor (GcgR) agonist, which allowed for in vivo dissection of glucagon action. As expected, chronic GcgR agonism in mice resulted in hyperglycemia and lower body fat and plasma cholesterol. Notably, GcgR activation also raised hepatic expression and circulating levels of fibroblast growth factor 21 (FGF21). This effect was retained in isolated primary hepatocytes from wild-type (WT) mice, but not GcgR knockout mice. We confirmed this link in healthy human volunteers, where injection of natural glucagon increased plasma FGF21 within hours. Functional relevance was evidenced in mice with genetic deletion of FGF21, where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed in WT mice. Taken together, these data reveal for the first time that glucagon controls glucose, energy, and lipid metabolism at least in part via FGF21-dependent pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that chronic GCG receptor agonism increased circulating FGF21 in mice and acute glucagon administration transiently increased FGF21 levels in humans25.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [25]
Citations
Cites
1 retracted
Berglund, E. D., Kang, L., Lee-Young, R. S., Hasenour, C. M., Lustig, D. G., Lynes, S. E., Donahue, E. P., Swift, L. L., Charron, M. J., & Wasserman, D. H. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00263.2010 · Cited by 100
RetractedFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · cited 1×
“Recent studies suggest that, like glucagon, FGF21 signaling regulates glucose, lipid, cholesterol, and bile acid metabolism (14,15), implicating FGF21 as an attractive drug candidate for metabolic disease.”
BackgroundSelf-citationInagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Disorders of motility and muscle tone with special reference to the corpus striatum
Wilson, S. A. K. (1925) · The Lancet · Cited by 1,409
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Self-citationThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · cited 2×
“FGF21 pharmacology reduces hyperglycemia, dyslipidemia, and plasma glucagon in diabetic mice and nonhuman primates (9).”
BackgroundSelf-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Cited by
Items 101–200 of 245
A GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes
Zhao, S., Yan, Z., Du, Y., Li, Z., Tang, C., Jing, L., Sun, L., Yang, Q., Tang, X., Yuan, Y., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15860 · Cited by 30
Human brown adipose tissue — function and therapeutic potential in metabolic disease
Bhatt, P. S., Dhillo, W. S., & Salem, V. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.07.004 · Cited by 40
Whytock, K. L., Carnero, E. A., Vega, R. B., Tillner, J., Bock, C., Chivukula, K., Yi, F., Meyer, C., Smith, S. R., & Sparks, L. M. (2021) · Obesity · doi:10.1002/oby.23141 · Cited by 30
Wang, R., Yi, X., Li, X., & Jiang, X. (2015) · PubMed Central · Cited by 29
Effects of 13-Hour Hyperglucagonemia on Energy Expenditure and Hepatic Glucose Production in Humans
Chakravarthy, M., Parsons, S., Lassman, M. E., Butterfield, K., Lee, A. Y. H., Chen, Y., Previs, S., Spond, J., Yang, S., Bock, C., et al. (2017) · Diabetes · doi:10.2337/db16-0746 · Cited by 28
“Additional possible explanations for the inconsistent findings between the present and previous studies (20, 21) are differences in the route of glucagon administration leading to different pharmacokinetics and differences in the study populations, including an exclusively male population in the present study versus a…”
BackgroundResultGluco-metabolic effects of oral and intravenous alcohol administration in men
Lanng, A. R., Gasbjerg, L. S., Bergmann, N. C., Bergmann, S., Helsted, M. M., Gillum, M. P., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2019) · Endocrine Connections · doi:10.1530/ec-19-0317 · Cited by 32
Patel, V., Joharapurkar, A., Kshirsagar, S., Sutariya, B., Patel, M., Pandey, D., Patel, H., Ranvir, R., Kadam, S., Patel, D., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.01.004 · Cited by 27
Single-Molecule Combinatorial Therapeutics for Treating Obesity and Diabetes
Tschöp, M., & DiMarchi, R. (2017) · Diabetes · doi:10.2337/dbi16-0068 · Cited by 27
Self-citationEffect of circulating glucagon and free fatty acids on hepatic FGF21 production in dairy cows
Caixeta, L. S., Giesy, S. L., Krumm, C. S., Perfield, J. W., Butterfield, A. M., Schoenberg, K. M., Beitz, D. C., & Boisclair, Y. R. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00197.2017 · Cited by 32
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
McGlone, E. R., Bloom, S. R., & Tan, T. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0365 · Cited by 30
“GCGR −/− mice have elevated plasma fibroblast growth factor 21 (FGF-21) (Omar et al. 2013), which cannot be due to hyperglucagonaemia because glucagon normally increases plasma and hepatic expression of FGF-21 via a direct effect on the glucagon receptor (Habegger et al. 2013, Cyphert et al. 2014).”
BackgroundGlucagon-Receptor Signaling Reverses Hepatic Steatosis Independent of Leptin Receptor Expression
Nason, S. R., Kim, T., Antipenko, J. P., Finan, B., DiMarchi, R., Hunter, C. S., & Habegger, K. M. (2020) · Endocrinology · doi:10.1210/endocr/bqz013 · Cited by 26
Self-citationLi, E., Wang, T., Wang, F., Wang, T., Sun, L., Li, L., Niu, S., & Zhang, J. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0077-2 · Cited by 26
Jeon, J. Y., Choi, S., Ha, E. S., Kim, T. H., Jung, J. G., Han, S. J., Kim, H. J., Kim, D. J., KANG, Y. Y., & Lee, K. W. (2016) · Endocrine · doi:10.1007/s12020-015-0845-x · Cited by 31
Antiretroviral therapy potentiates high-fat diet induced obesity and glucose intolerance
Pepin, M. E., Padgett, L. E., McDowell, R. E., Burg, A. R., Brahma, M. K., Holleman, C., Kim, T., Crossman, D., Kutsch, O., Tse, H. M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.04.006 · Cited by 25
Self-citationElvert, R., Bossart, M., Herling, A. W., Weiss, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 24
Use of FGF21 analogs for the treatment of metabolic disorders: a systematic review and meta-analysis
Carbonetti, M. P., Almeida‐Oliveira, F., & Majerowicz, D. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2022-0493 · Cited by 26
“First, FGF21 knockout mice exhibit increased glucose tolerance (18).”
BackgroundPharmacological Actions of Glucagon-Like Peptide-1, Gastric Inhibitory Polypeptide, and Glucagon
Sekar, R., Singh, K., Arokiaraj, A. W. R., & Chow, B. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.05.002 · Cited by 27
Pérez‐Martí, A., Sandoval, V., Marrero, P. F., Haro, D., & Relat, J. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0034 · Cited by 30
Vienberg, S. G., Jacobsen, S. H., Worm, D., Hvolris, L., Naver, L., Almdal, T., Hansen, D. L., Wulff, B. S., Clausen, T. R., Madsbad, S., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.13241 · Cited by 28
Ali, M. M., Hafez, A., Abdelgalil, M. S., Hasan, M. T., El-Ghannam, M. M., Ghogar, O. M., Elrashedy, A. A., & Abd-ElGawad, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01031-5 · Cited by 23
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Knerr, P. J., Finan, B., Gelfanov, V. M., Pérez–Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.047 · Cited by 24
Self-citationGlucagon Prevents Cytotoxicity Induced by Methylglyoxal in a Rat Neuronal Cell Line Model
Mohiuddin, M. S., Himeno, T., Yamada, Y., Morishita, Y., Kondo, M., Tsunekawa, S., Kato, Y., Nakamura, J., & Kamiya, H. (2021) · Biomolecules · doi:10.3390/biom11020287 · Cited by 23
“Other than gluconeogenesis, glucagon has pleiotropic effects: cardioprotection [7,8] and reduction of obesity [9].”
Akbar, H., Batistel, F., Drackley, J. K., & Loor, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139963 · Cited by 28
Rivero‐Gutiérrez, B., Haller, A. M., Holland, J., Yates, E., Khrisna, R., Habegger, K. M., DiMarchi, R. D., D’Alessio, D. A., & Pérez–Tilve, D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.012 · Cited by 24
Self-citationOcker, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i3.279 · Cited by 28
Current and Emerging Treatment Options in Diabetes Care
Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 23
Self-citationPeptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity
Soni, H. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.08.005 · Cited by 24
Valdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists
Yang, B. S., Gelfanov, V. M., Pérez–Tilve, D., DUBOIS, B. N., Rohlfs, R., Levy, J. J., Douros, J. D., Finan, B., Mayer, J. P., & DiMarchi, R. D. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02069 · Cited by 22
Self-citationFrampton, J., Izzi‐Engbeaya, C. N., Salem, V., Murphy, K. G., Tan, T., & Chambers, E. S. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01223-y · Cited by 23
Arafat, A. M., Weickert, M. O., Adamidou, A., Otto, B., Perschel, F. H., Spranger, J., Möhlig, M., & Pfeiffer, A. F. H. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1635 · Cited by 24
Self-citationRelationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus
Guo, C. Y., Zhao, L., Li, Y., Deng, X., & Yuan, G. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29879 · Cited by 22
“Studies have shown that EE can regulate the glucagon FGF21 axis (Habegger et al., 2013).”
BackgroundPedersen, C., Porsgaard, T., Thomsen, M., ROSENKILDE, M. M., & Roed, N. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194468 · Cited by 21
Mobasher, M. A., de Toro‐Martín, J., González‐Rodríguez, Á., Ramos, S., Letzig, L. G., James, L. P., Muntané, J., Álvarez, C., & Valverde, Á. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539189 · Cited by 21
Ippagunta, S. M., Kharitonenkov, A., Adams, A. C., & Hillgartner, F. B. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy022 · Cited by 23
Self-citationBeaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“6 attenuated thermogenic response to acute glucagon administration (24, 43).”
BackgroundLi, W., Kirchner, T., Ho, G., Bonilla, F., D'Aquino, K., Littrell, J., Zhang, R., Jian, W., Qiu, X., Zheng, S., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14173 · Cited by 20
Meal sugar-protein balance determines postprandial FGF21 response in humans
Ramne, S., Duizer, L., Nielsen, M. S., Jørgensen, N. R., Svenningsen, J. S., Grarup, N., Sjödin, A. M., Raben, A., & Gillum, M. P. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2023 · Cited by 21
Impact of FGF21 on glycemic control
Strowski, M. Z. (2017) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2017-0001 · Cited by 20
Islet transplantation into brown adipose tissue can delay immune rejection
Kepple, J. D., Barra, J. M., Young, M. E., Hunter, C. S., & Tse, H. M. (2022) · JCI Insight · doi:10.1172/jci.insight.152800 · Cited by 20
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[59] In addition, glucagon decreases lipid stores in the liver and modifies hepatocyte metabolism to mitigate the severity of non‑alcoholic steatohepatitis (NASH), a prevalent obesity‑related condition.”
Andersen, B., Omar, B. A., Rakipovski, G., Raun, K., & Åhrén, B. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.07.003 · Cited by 21
“Both FGF21 and glucagon independently influence circulating free fatty acids, and the presence of ketone bodies is seen in severe insulin deficiency (Gaich et al., 2013; Habegger et al., 2013).”
BackgroundIbarra‐Reynoso, L. D. R., Pisarchyk, L., Pérez-Luque, E. L., Garay‐Sevilla, M. E., & Malacara, J. M. (2015) · Nutrition & Metabolism · doi:10.1186/s12986-015-0027-0 · Cited by 24
Stahel, P., Lee, S. J., Sud, S. K., Floh, A., & Dash, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13661 · Cited by 18
Welles, J. E., Dennis, M. D., Jefferson, L. S., & Kimball, S. R. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00555.2019 · Cited by 18
Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes
Ye, G., Ly, N. S., Li, J., & Arends, R. H. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01094-y · Cited by 16
Wei, S., Li, C., Luo, X., Yang, L., Yu, L., Wang, Q., Meng, Z., Wang, T., & Chen, Y. (2021) · 中国科学通报:英文版 · doi:10.1016/j.scib.2021.12.024 · Cited by 16
Li, M., Qureshi, A. R., Ellis, E. C. S., & Axelsson, J. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft337 · Cited by 17
McCarty, M. F. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0056 · Cited by 17
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Role of peptide hormones in the adaptation to altered dietary protein intake
Rose, A. J. (2019) · Nutrients · doi:10.3390/nu11091990 · Cited by 15
Ye, X., Chen, Y., Qi, J., Zhu, S., Wu, Y., Xiong, J., Hu, F., Guo, Z., & Liang, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175811 · Cited by 14
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“…stimulating hepatic Fibroblast Growth Factor 21 (FGF21) secretion (hormone will be described in paragraph 5.1.) and central FGF21 receptor actions [130, 137]; and increasing energy expenditure by increasing basal metabolic rate and inducing thermogenesis in brown adipose tissue (BAT), as shown in…”
InfluentialGlucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Richter, M. M., Kemp, I. M., Heebøll, S., Winther‐Sørensen, M., Kjeldsen, S. A. S., Jensen, N. J., Nybing, J. D., Linden, F. H., Høgh‐Schmidt, E., Boesen, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155915 · Cited by 15
Adipose Tissue, at the Core of the Action of Incretin and Glucagon-Based Anti-Obesity Drugs
Villarroya, F., Peyrou, M., & Giralt, M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00660-w · Cited by 15
“FGF21 is a powerful inducer of thermogenic acti - vation in adipose tissues [159 , 160 ], and results obtained from FGF21-null mice showed that FGF21 critically medi - ates the effects of GCG on BAT activity and WAT brown - ing [103 , 104].”
Central and Peripheral Glucagon Reduces Hyperlipidemia in Rats and Hamsters
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, H., Pandey, D., Patel, D. N., Shah, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2017) · Drug Research · doi:10.1055/s-0043-102405 · Cited by 14
“This observation confirms the earlier reports that glucagon agonism creates a negative energy balance in obese and hyperlipidemic conditions [19].”
BackgroundResultQuiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
Once upon a time: the glucagon stimulation test in diagnosing adult GH deficiency
Cuboni, D., Caputo, M., Ghigo, E., Aimaretti, G., & Gasco, V. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02322-5 · Cited by 13
“Glucagon has been shown to increase hepatic secretion of FGF-21 [29], and some of its metabolic effects are thought to occur, at least partially, through the FGF-21-dependent pathway [30].”
BackgroundLaker, R. C., Egolf, S., Will, S., Lantier, L., McGuinness, O. P., Brown, C. L., Bhagroo, N. V., Oldham, S. N., Kuszpit, K. K., Alfaro, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59773-4 · Cited by 18
A glucagon analogue decreases body weight in mice via signalling in the liver
Hinds, C. E., Owen, B. M., Hope, D. C. D., Pickford, P., Jones, B. J., Tan, T., MINNION, J. S., & Bloom, S. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01912-0 · Cited by 15
Class B1 GPCRs: insights into multireceptor pharmacology for the treatment of metabolic disease
Sangwung, P., Ho, J. D., Siddall, T., Lin, J., Tomás, A., Jones, B. J., & Sloop, K. W. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00371.2023 · Cited by 15
Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control
Lee, S. H., Park, H. Y., Yun, J. H., & Kyoung, E. J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1645041 · Cited by 14
Camacho, R. C., You, S.-H., D’Aquino, K. E., Li, W., Wang, Y., Gunnet, J. W., Littrell, J. B., Qi, J. S., Kang, L., Jian, W., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1794687 · Cited by 13
OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes
Melander, S. A., Kayed, A., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176215 · Cited by 11
An organism-wide atlas of hormonal signaling based on the mouse lemur single-cell transcriptome
Liu, S., Ezran, C., Wang, M. F. Z., Li, Z., Awayan, K., Agarwal, S., Agrawal, A., Al‐Moujahed, A., Alam, A. A., Albertelli, M. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46070-9 · Cited by 14
Ueno, S., Seino, Y., Hidaka, S., Maekawa, R., Takano, Y., Yamamoto, M., Hori, M., Yokota, K., Masuda, A., Himeno, T., et al. (2022) · Nutrients · doi:10.3390/nu14050975 · Cited by 12
Preproglucagon Products and Their Respective Roles Regulating Insulin Secretion
Bethea, M. M., Bozadjieva-Kramer, N., & Sandoval, D. A. (2021) · Endocrinology · doi:10.1210/endocr/bqab150 · Cited by 12
A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Characterization of LY3324954 a long-acting glucagon-receptor agonist
Roell, W. C., Coşkun, T., Kim, T., O’Farrell, L. S., Martin, J. A., Nason, S. R., Hernandez-Alamillo, J., Dhantu, S., Drucker, D. J., Sloop, K. W., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102073 · Cited by 12
Self-citationZhang, J., Sanan, S., Csanalosi, M., Zheng, C., & Pfeiffer, A. F. H. (2025) · Endocrinology · doi:10.1210/endocr/bqaf130 · Cited by 15
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, H., Pandey, D., Patel, D. N., Sutariya, B., Patel, M. S., Bahekar, R. H., & Jain, M. R. (2017) · Drug Research · doi:10.1055/s-0043-118808 · Cited by 11
“Glucagon controls glucose, energy, and lipid metabolism in part via FGF21-dependent pathways [28].”
BackgroundHan, C., Sun, Y., Yang, Q., Zhou, F. L., Chen, X., Wu, L., Sun, L., & Han, J. D. J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00995 · Cited by 12
LDB1 Regulates Energy Homeostasis During Diet-Induced Obesity
Loyd, C., Liu, Y., Kim, T., Holleman, C. L., Galloway, J., Bethea, M. M., Ediger, B. N., Swain, T. A., Tang, Y., Stoffers, D. A., et al. (2016) · Endocrinology · doi:10.1210/en.2016-1791 · Cited by 11
Self-citationZhou, Y., Tu, L., Wang, X., Xu, J., Xu, S., Ning, X., Xiong, X., & Zheng, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01399 · Cited by 10
Parsing the Potential Neuroendocrine Actions of FGF21 in Primates
Gillum, M. P. (2018) · Endocrinology · doi:10.1210/en.2018-00208 · Cited by 9
Pokhrel, S., Dilts, M., Stahl, Z., Boehme, S., Frame, G., Chiang, J. Y. L., & Ferrell, J. M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000138 · Cited by 11
Practical prospects for boosting hepatic production of the “pro-longevity” hormone FGF21
McCarty, M. F. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0057 · Cited by 13
Cai, X., Li, C., Zhou, J., Dai, Y., Avraham, Y., Sun, L., Liu, C., Tong, J., Wang, Y., Bi, X., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103538 · Cited by 11
Poloczek, J., Kazura, W., Kwaśnicka, E., Gumprecht, J., Jochem, J., & Stygar, D. M. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5527107 · Cited by 10
“Therefore, the authors rejected the thesis that the level of FGF21 could have been regulated by the concentration of glucagon [72], which was postulated in earlier studies [73].”
ResultXia, M., Erickson, A., Yi, X., & Moreau, R. F. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.12.004 · Cited by 11
Liu, J., Jiang, J., Li, Y., Chen, Q., Yang, T., Lei, Y., He, Z., Wang, X., Na, Q., Lao, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1439255 · Cited by 11
Research progress on the role of FGF21 in insulin resistance
Zhang, H., Zhu, R., Sun, Q., & Du, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1619462 · Cited by 16
Glucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
Reinhard, M., Frystyk, J., Jespersen, B., Randers, E., Bibby, B. M., & Ivarsen, P. (2015) · Clinical Endocrinology · doi:10.1111/cen.12737 · Cited by 9
Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes
Wu, Y., Chan, A. Y., Hauke, J., Aung, O. H., Foollee, A., Cleofe, M. A. S., Stölting, H., Han, M., Jeppe, K. J., Barlow, C. K., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102064 · Cited by 10
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“Of note, glucagon appears to act as an FGF21 secretagogue in both animal models and humans, 111 which may partly mediate its effects on liver fat and fibrosis at the molecular level.”
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
Commentary: FGF21 Holds Promises for Treating Obesity-related Insulin Resistance and Hepatosteatosis
Alisi, A., Panera, N., & Nobili, V. (2013) · Endocrinology · doi:10.1210/en.2013-1828 · Cited by 8
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“Therefore, in addition to the proposed liver-to-brain mechanism, it is possible that there are liver to adipose mechanisms capable of increasing EE and browning of adipose tissue via bile acid [130] and FGF21 production at the liver following GCGR activation [50].”
InfluentialSelf-citationRegulation of feeding and therapeutic application of bioactive peptides
Ueno, H., Zhang, W., & Nakazato, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108187 · Cited by 7
Regulation of cholesterol metabolism: New players for an old physiological process
Parente, M., Tonini, C., Segatto, M., & Pallottini, V. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30477 · Cited by 9
“70 73 Literature data reports that glucagon enhances the degradation of LDL by increasing LDLR activity 74 and increases the expression of hepatic LDLR by promoting a signaling pathway that regulates PCSK9 degradation.”
BackgroundKim, T., Nason, S. R., ANTIPENKO, J. P., Finan, B., Shalev, A., DiMarchi, R. D., & Habegger, K. M. (2022) · Diabetes · doi:10.2337/db21-1018 · Cited by 12
Self-citationOlivares, S., & Henkel, A. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.006 · Cited by 7
Targeting the Enteroendocrine System for Treatment of Obesity
Miedzybrodzka, E. L., Gribble, F. M., & Reimann, F. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2022_583 · Cited by 5
Adipokine-Cytokine Profile in Patients with Unstable Atherosclerotic Plaques and Abdominal Obesity
Garbuzova, E. V., Шрамко, В. С., Kashtanova, E. V., Polonskaya, Y. V., Stakhneva, E. M., Кургузов, А. В., Murashov, I. S., Chernyavsky, A. M., & Ragino, Y. I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108937 · Cited by 7
“The coagonist of GL -1 and glucagon also increased the expression of LDL receptors, increased the absorpti n of LDL from the bloodstream, and decreased the level of circulating lipids [19].”
BackgroundWu, Y., Foollee, A., Chan, A. Y., Hille, S. S., Hauke, J., Challis, M. P., Johnson, J. L., Yaron, T. M., Mynard, V., Aung, O. H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52703-w · Cited by 8
Twice the benefits with twincretins?
Stümvoll, M., & Tschöp, M. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32466-8 · Cited by 25
Self-citationMoreno-Lopez, M., Louvet, I., Delalleau, N., Acosta-Montalvo, A., Thévenet, J., Pasquetti, G., Gmyr, V., Kerr-Conte, J. A., Pattou, F. N., Bonner, C., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16089 · Cited by 7
“26 Our study suggests the glucagon-FGF21 axis may mediate some effects of SGLT2i.”
Alamgir, M., Sohal, A., & Kowdley, K. V. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560039 · Cited by 6
“39,40 These changes result in increased fatty acid oxidation and triglyceride synthesis in the liver.”
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Izzi‐Engbeaya, C. N., Salem, V., Atkar, R. S., Coello, C. S., Thomas, D., Comninos, A. N., Buckley, A. J., Rabiner, E. A., Gunn, R. N., Tan, T., et al. (2015) · Endocrine Abstracts · doi:10.1530/endoabs.38.oc4.5 · Cited by 4
Metadata
- Authors
- Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., Krishna, R., Arafat, A. M., Konkar, A., Belli, S., Kapps, M., Woods, S. C., Hofmann, S. M., D’Alessio, D., Pfluger, P. T., Perez-Tilve, D., Seeley, R. J., Konishi, M., Itoh, N., Kharitonenkov, A., Spranger, J., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- University of Cincinnati (US)
- Helmholtz Munich (DE)
- Eli Lilly (United States) (US)
- Indiana University Bloomington (US)
- Charité – Universitätsmedizin Berlin (DE)
- F. Hoffmann-La Roche AG (CH)
- Metabolic Disease Institute, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio
- Kyoto University (JP)
- Corresponding author
- Tschöp, Matthias H.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1453-1463
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636653
- OpenAlex
- W2131192628
- Cited by
- 245
- References
- 38
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 21 · 2023: 15 · 2022: 17 · 2021: 19 · 2020: 16 · 2019: 16 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 27 · 2014: 22 · 2013: 12
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- F. Hoffmann-La Roche
- University of Cincinnati
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, glucagon, glucagon receptor agonist, glucose homeostasis, lipid metabolism, weight loss, hyperglycemia, obesity, serum cholesterol, energy metabolism
- MeSH terms
- Adult, Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Fibroblast Growth Factors, Glucagon, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Mice, Mutant Strains, Obesity, Peptides, Recombinant Proteins, Receptors, Glucagon, Mice, Knockout, Cross-Over Studies, Anti-Obesity Agents, Hepatocytes, Mice, Rats, HEK293 Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.